APA (7th ed.) Citation

N, V., AB, T., G, B., DG, B., LK, S., J, P., . . . AVS, H. (2025). Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: Two phase 1, first-in-human trials. The Lancet. Microbe, 6(3), 100868. https://doi.org/10.1016/S2666-5247(24)00084-3

Chicago Style (17th ed.) Citation

N, Venkatraman, et al. "Evaluation of a Novel Malaria Anti-sporozoite Vaccine Candidate, R21 in Matrix-M Adjuvant, in the UK and Burkina Faso: Two Phase 1, First-in-human Trials." The Lancet. Microbe 6, no. 3 (2025): 100868. https://doi.org/10.1016/S2666-5247(24)00084-3.

MLA (9th ed.) Citation

N, Venkatraman, et al. "Evaluation of a Novel Malaria Anti-sporozoite Vaccine Candidate, R21 in Matrix-M Adjuvant, in the UK and Burkina Faso: Two Phase 1, First-in-human Trials." The Lancet. Microbe, vol. 6, no. 3, 2025, p. 100868, https://doi.org/10.1016/S2666-5247(24)00084-3.